Advertisement

Investigational New Drugs

, Volume 30, Issue 2, pp 708–713 | Cite as

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

  • Takashi Sasaki
  • Hiroyuki Isayama
  • Yousuke Nakai
  • Suguru Mizuno
  • Keisuke Yamamoto
  • Hiroshi Yagioka
  • Yoko Yashima
  • Kazumichi Kawakubo
  • Hirofumi Kogure
  • Osamu Togawa
  • Saburo Matsubara
  • Yukiko Ito
  • Naoki Sasahira
  • Kenji Hirano
  • Takeshi Tsujino
  • Nobuo Toda
  • Minoru Tada
  • Masao Omata
  • Kazuhiko Koike
PHASE II STUDIES

Summary

Gemcitabine is widely used for the treatment of advanced biliary tract cancer (BTC) as first-line chemotherapy. However, there is no standard chemotherapy for patient with advanced BTC refractory to gemcitabine. We conducted a multicenter phase II study of S-1 monotherapy as second-line chemotherapy for patients with advanced BTC that were refractory to gemcitabine. S-1 was administered orally at a dose of 80 mg/m2 for 28 days, followed by 14 days of rest. This regimen was repeated every 6 weeks. Tumor response was assessed every two cycles using the Response Evaluation Criteria in Solid Tumors version 1.0. Twenty-two patients were enrolled between March 2007 and January 2010, with 14 patients (64%) representing cases of recurrence after surgery. The overall response rate was 22.7%, and the overall disease control rate was 50.0%. The median overall survival time was 13.5 months (95% CI, 7.1–23.1 months) and the median time-to-progression was 5.4 months (95% CI, 2.6–17.2 months). Grade 3/4 toxicities included neutropenia (5%) and anemia (5%). The most common non-hematological toxicities were nausea (27%), anorexia (55%), and pigmentation (32%). In conclusion, S-1 monotherapy is feasible and moderately efficacious second-line chemotherapy for advanced BTC.

Keywords

Biliary tract cancer S-1 Gemcitabine Second-line 

Notes

Conflict of interest statement

None declared.

References

  1. 1.
    National Cancer Center. Cancer statistics in Japan 2009. http://www.fpcr.or.jp/publication/statistics.html. Accessed 1 August, 2010.
  2. 2.
    Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96(6):896–902PubMedCrossRefGoogle Scholar
  3. 3.
    Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23(10):2332–2338PubMedCrossRefGoogle Scholar
  4. 4.
    Andre T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O et al (2008) Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 99(6):862–867PubMedCrossRefGoogle Scholar
  5. 5.
    Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O et al (2010) Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65(6):1101–1107PubMedCrossRefGoogle Scholar
  6. 6.
    Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281PubMedCrossRefGoogle Scholar
  7. 7.
    Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103(4):469–474PubMedCrossRefGoogle Scholar
  8. 8.
    Lee MA, Woo IS, Kang JH, Hong YS, Lee KS (2004) Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Jpn J Clin Oncol 34(9):547–550PubMedCrossRefGoogle Scholar
  9. 9.
    Paule B, Herelle MO, Rage E, Ducreux M, Adam R, Guettier C et al (2007) Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72(1–2):105–110PubMedCrossRefGoogle Scholar
  10. 10.
    Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, et al. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2010 (in press).Google Scholar
  11. 11.
    Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H et al (2010) Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs (in press).Google Scholar
  12. 12.
    Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91(10):1769–1774PubMedCrossRefGoogle Scholar
  13. 13.
    Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T et al (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62(5):849–855PubMedCrossRefGoogle Scholar
  14. 14.
    Park I, Lee JL, Ryu MH, Kim TW, Chang HM, Lee SS et al (2009) Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients. Oncology 76(2):126–132PubMedCrossRefGoogle Scholar
  15. 15.
    Sasaki T, Isayama H, Yashima Y, Yagioka H, Kogure H, Arizumi T et al (2009) S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 77(1):71–74PubMedCrossRefGoogle Scholar
  16. 16.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRefGoogle Scholar
  17. 17.
    Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38(1):143–151PubMedCrossRefGoogle Scholar
  18. 18.
    Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T et al (2010) A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer. Proc Am Soc Clin Oncol 28:15s, abstract no: 4145Google Scholar
  19. 19.
    Yonemoto N, Furuse J, Okusaka T, Yamao Funakoshi A, Ohkawa S et al (2007) A multi-centerretrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 37(11):843–851PubMedCrossRefGoogle Scholar
  20. 20.
    Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y et al (2010) Prognostic factors in patientswith advanced biliary tract cancer receiving chemotherapy. Cancer Chemother Pharmacol (in press)Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Takashi Sasaki
    • 1
  • Hiroyuki Isayama
    • 1
  • Yousuke Nakai
    • 1
  • Suguru Mizuno
    • 1
  • Keisuke Yamamoto
    • 1
  • Hiroshi Yagioka
    • 2
  • Yoko Yashima
    • 3
  • Kazumichi Kawakubo
    • 1
  • Hirofumi Kogure
    • 1
  • Osamu Togawa
    • 1
  • Saburo Matsubara
    • 4
  • Yukiko Ito
    • 3
  • Naoki Sasahira
    • 1
  • Kenji Hirano
    • 1
  • Takeshi Tsujino
    • 3
  • Nobuo Toda
    • 5
  • Minoru Tada
    • 1
  • Masao Omata
    • 6
  • Kazuhiko Koike
    • 1
  1. 1.Department of Gastroenterology, Graduate School of MedicineThe University of TokyoTokyoJapan
  2. 2.Department of GastroenterologyJR Tokyo General HospitalTokyoJapan
  3. 3.Department of GastroenterologyJapanese Red Cross Medical CenterTokyoJapan
  4. 4.Department of GastroenterologyKanto Central HospitalTokyoJapan
  5. 5.Department of GastroenterologyMitsui Memorial HospitalTokyoJapan
  6. 6.Yamanashi Prefectural Hospital OrganizationKofuJapan

Personalised recommendations